Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Connect Biopharma Holdings (CNTB) Non-Current Assets (2023 - 2025)

Connect Biopharma Holdings' Non-Current Assets history spans 3 years, with the latest figure at $4.8 million for Q3 2025.

  • For Q3 2025, Non-Current Assets changed N/A year-over-year to $4.8 million; the TTM value through Dec 2023 reached $4.9 million, changed N/A, while the annual FY2024 figure was $4.3 million, 12.15% down from the prior year.
  • Non-Current Assets for Q3 2025 was $4.8 million at Connect Biopharma Holdings, up from $4.3 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $4.9 million in Q4 2023 and bottomed at $4.3 million in Q4 2024.
  • The 3-year median for Non-Current Assets is $4.8 million (2025), against an average of $4.7 million.
  • The largest YoY upside for Non-Current Assets was 12.15% in 2024 against a maximum downside of 12.15% in 2024.
  • A 3-year view of Non-Current Assets shows it stood at $4.9 million in 2023, then dropped by 12.15% to $4.3 million in 2024, then grew by 10.2% to $4.8 million in 2025.
  • Per Business Quant, the three most recent readings for CNTB's Non-Current Assets are $4.8 million (Q3 2025), $4.3 million (Q4 2024), and $4.9 million (Q4 2023).